Azenta Q2 Earnings Call Highlights

• 5 aesculapian stocks increasing net by triple digits

Azenta (NASDAQ:AZTA) reported fiscal second-quarter 2026 results that absorption said fell abbreviated of expectations, citing execution shortfalls and a cautious request environment—particularly successful North America—along with ongoing weakness successful superior instrumentality spending.

“Candidly, we are not satisfied with our 2nd 4th results,” President and CEO John Marotta said. Organic gross declined 3% successful the 4th and adjusted EBITDA borderline was 5.4%, which Marotta said did not conscionable the company’s expectations. He attributed the show to “execution-related shortfalls wrong our control” arsenic good arsenic “a much cautious, prolonged request environment,” particularly successful North America wherever lawsuit spending and probe backing stay constrained.

Quarterly show and cardinal drivers

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Executive Vice President and CFO Lawrence Lin said full reported gross was $145 million, up 1% twelvemonth implicit year, including $1 million from the UK Biocentre acquisition. Excluding UK Biocentre and overseas exchange, gross was down 3% organically. Non-GAAP EPS was a loss of $0.04.

Lin said adjusted EBITDA was $7.8 million, oregon 5.4% of revenue, down 320 ground points twelvemonth implicit year. He attributed the borderline diminution chiefly to little volumes and reduced fixed-cost absorption, arsenic good arsenic prime rework costs tied to automated retention systems and an summation successful inventory reserves. Gross borderline was 44.3%, down 110 ground points versus the anterior year, including astir $2 million of prime costs associated with automated retention rework.

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

Free currency flow, including B Medical, was $5 million successful the quarter, which Lin said was driven by working-capital improvements and higher deferred revenue. The institution ended the 4th with $565 million successful currency equivalents and marketable securities and no indebtedness outstanding.

Segment results: spot successful biorepositories, unit successful North America Multiomics

In Sample Management Solutions (SMS), gross was $81 million, up 2% reported and down 3% organically. Lin said Biorepository Solutions—roughly 40% of the SMS segment—posted high single-digit growth, portion Consumables and Instruments delivered humble maturation supported by request crossed the installed base. Offsetting that, helium said orders for automated and cryogenic store systems were pressured by little superior spending, resulting successful a low double-digit decline successful halfway products. SMS gross borderline was 47.4%, up 40 ground points, which Lin said reflected improved biorepository borderline and an accounting accommodation that much than offset headwinds from little volumes, prime rework, and an inventory reserve.